|
|
Follow-up of patiens after COVID-19 monoclonal antibodies administration
Minaříková, Jiřina ; Zimčíková, Eva (advisor) ; Hendrychová, Tereza (referee)
Follow-up of patients after COVID-19 monoclonal antibodies administration Author: Jiřina Minaříková Supervisor: PharmDr. Eva Zimčíková, Ph.D. Consultant: PharmDr. Petra Rozsívalová Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Social and Clinical Pharmacy Keywords: COVID-19, coronavirus, monoclonal antibodies, casirivimab and imdevimab, REGN-COV2 Introduction: At height of COVID-19 pandemic surge of Delta variant, monoclonal antibodies became a vital treatment option for SARS-CoV-2 positive outpatients at high risk of severe disease progression. Casirivimab and imdevimab (C/I) were used as an unauthorised medicinal product REGN-COV2 under European Medicines Agency emergency use authorisation (EUA). There was paucity of real-world data on safety and effectiveness. Objective: The study aimed to describe REGN-COV2 drug safety, self-reported symptom burden in SARS-CoV-2 positive outpatients within 90 days post C/I infusion. Methods: Prospective multicentric study of SARS-CoV-2 positive outpatients with mild symptoms at high-risk of severe COVID-19 progression (defined criteria under EUA authorization for C/I ambulatory administration) was conducted from September 2021 till April 2022 in three teaching hospitals in Czech Republic and Slovakia. The data collected...
|
|
|
Follow-up of patiens after COVID-19 monoclonal antibodies administration
Minaříková, Jiřina ; Zimčíková, Eva (advisor) ; Hendrychová, Tereza (referee)
Follow-up of patients after COVID-19 monoclonal antibodies administration Author: Jiřina Minaříková Supervisor: PharmDr. Eva Zimčíková, Ph.D. Consultant: PharmDr. Petra Rozsívalová Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Social and Clinical Pharmacy Keywords: COVID-19, coronavirus, monoclonal antibodies, casirivimab and imdevimab, REGN-COV2 Introduction: At height of COVID-19 pandemic surge of Delta variant, monoclonal antibodies became a vital treatment option for SARS-CoV-2 positive outpatients at high risk of severe disease progression. Casirivimab and imdevimab (C/I) were used as an unauthorised medicinal product REGN-COV2 under European Medicines Agency emergency use authorisation (EUA). There was paucity of real-world data on safety and effectiveness. Objective: The study aimed to describe REGN-COV2 drug safety, self-reported symptom burden in SARS-CoV-2 positive outpatients within 90 days post C/I infusion. Methods: Prospective multicentric study of SARS-CoV-2 positive outpatients with mild symptoms at high-risk of severe COVID-19 progression (defined criteria under EUA authorization for C/I ambulatory administration) was conducted from September 2021 till April 2022 in three teaching hospitals in Czech Republic and Slovakia. The data collected...
|
guest ::
